Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer. (11th January 2022)

Record Type:: Journal Article
Title:: Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer. (11th January 2022)
Main Title:: Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer
Authors:: Chung, Clement
Abstract:
Is Part Of:: American journal of health-system pharmacy. Volume 79:Number 10(2022)
Journal:: American journal of health-system pharmacy
Issue:: Volume 79:Number 10(2022)
Issue Display:: Volume 79, Issue 10 (2022)
Year:: 2022
Volume:: 79
Issue:: 10
Issue Sort Value:: 2022-0079-0010-0000
Page Start:: 717
Page End:: 718
Publication Date:: 2022-01-11
Subjects:: ad-trastuzumab emtansine -- adjuvant -- early breast cancer -- HER2
Hospital pharmacies -- United States -- Periodicals
615.1
Journal URLs:: https://academic.oup.com/ajhp ↗
http://www.oxfordjournals.org/ ↗
DOI:: 10.1093/ajhp/zxac008 ↗
Languages:: English
ISSNs:: 1079-2082
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 26761.xml